Gert-Jan R Ten Kate1, Sven Bos2, Admir Dedic1, Lisan A Neefjes1, Akira Kurata3, Janneke G Langendonk2, Anho Liem4, Adriaan Moelker3, Gabriel P Krestin3, Pim J de Feyter5, Jeanine E Roeters van Lennep6, Koen Nieman5, Eric J Sijbrands2. 1. Department of Radiology, Erasmus Medical Centre, Rotterdam, the Netherlands; Interuniversitair Cardiologisch Instituut Nederland, Utrecht, the Netherlands; Department of Cardiology, Thorax Centre Rotterdam, Rotterdam, the Netherlands. 2. Department of Internal Medicine, Erasmus Medical Centre Rotterdam, Rotterdam, the Netherlands. 3. Department of Radiology, Erasmus Medical Centre, Rotterdam, the Netherlands. 4. Department of Cardiology, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. 5. Department of Radiology, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Cardiology, Thorax Centre Rotterdam, Rotterdam, the Netherlands. 6. Department of Internal Medicine, Erasmus Medical Centre Rotterdam, Rotterdam, the Netherlands. Electronic address: j.roetersvanlennep@erasmusmc.nl.
Abstract
BACKGROUND: Familial hypercholesterolemia is typically caused by LDL receptor (LDLR) mutations that result in elevated levels of LDL cholesterol (LDL-C). In homozygous FH, the prevalence of aortic valve calcification (AoVC) reaches 100% and is often symptomatic. OBJECTIVES: The objective of this study was to investigate the prevalence, extent, and risk-modifiers of AoVC in heterozygous FH (he-FH) that are presently unknown. METHODS: Asymptomatic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent CT computed tomography calcium scoring. AoVC was defined as the presence of calcium at the aortic valve leaflets. The extent of AoVC was expressed in Agatston units, as the AoVC-score. We compared the prevalence and extent of AoVC between cases and controls. In addition, we investigated risk modifiers of AoVC, including the presence of LDLR mutations without residual function (LDLR-negative mutations), maximum untreated LDL-cholesterol (maxLDL), LDL-C, blood pressure, and coronary artery calcification (CAC). RESULTS: We included 145 asymptomatic patients with he-FH (93 men; mean age 52 ± 8 years) and 131 non-familial hypercholesterolemia controls. The prevalence (%) and AoVC-score (median, IQR) were higher in he-FH patients than in controls: 41%, 51 (9-117); and 21%, 21 (3-49) (p < 0.001 and p = 0.007). Age, untreated maxLDL, CAC, and diastolic blood pressure were independently associated with AoVC. LDLR-negative mutational he-FH was the strongest predictor of the AoVC-score (OR: 4.81; 95% CI: 2.22 to 10.40; p = <0.001). CONCLUSIONS: Compared to controls, he-FH is associated with a high prevalence and a large extent of subclinical AoVC, especially in patients with LDLR-negative mutations, highlighting the critical role of LDL-C metabolism in AoVC etiology.
BACKGROUND:Familial hypercholesterolemia is typically caused by LDL receptor (LDLR) mutations that result in elevated levels of LDL cholesterol (LDL-C). In homozygous FH, the prevalence of aortic valve calcification (AoVC) reaches 100% and is often symptomatic. OBJECTIVES: The objective of this study was to investigate the prevalence, extent, and risk-modifiers of AoVC in heterozygous FH (he-FH) that are presently unknown. METHODS: Asymptomatic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent CT computed tomography calcium scoring. AoVC was defined as the presence of calcium at the aortic valve leaflets. The extent of AoVC was expressed in Agatston units, as the AoVC-score. We compared the prevalence and extent of AoVC between cases and controls. In addition, we investigated risk modifiers of AoVC, including the presence of LDLR mutations without residual function (LDLR-negative mutations), maximum untreated LDL-cholesterol (maxLDL), LDL-C, blood pressure, and coronary artery calcification (CAC). RESULTS: We included 145 asymptomatic patients with he-FH (93 men; mean age 52 ± 8 years) and 131 non-familial hypercholesterolemia controls. The prevalence (%) and AoVC-score (median, IQR) were higher in he-FH patients than in controls: 41%, 51 (9-117); and 21%, 21 (3-49) (p < 0.001 and p = 0.007). Age, untreated maxLDL, CAC, and diastolic blood pressure were independently associated with AoVC. LDLR-negative mutational he-FH was the strongest predictor of the AoVC-score (OR: 4.81; 95% CI: 2.22 to 10.40; p = <0.001). CONCLUSIONS: Compared to controls, he-FH is associated with a high prevalence and a large extent of subclinical AoVC, especially in patients with LDLR-negative mutations, highlighting the critical role of LDL-C metabolism in AoVC etiology.
Authors: Liv J Mundal; Anders Hovland; Jannicke Igland; Marit B Veierød; Kirsten B Holven; Martin Prøven Bogsrud; Grethe S Tell; Trond P Leren; Kjetil Retterstøl Journal: JAMA Cardiol Date: 2019-11-01 Impact factor: 14.676
Authors: Rodrigo Alonso; Rosa Argüeso; Pilar Álvarez-Baños; Ovidio Muñiz-Grijalvo; Jose Luis Diaz-Diaz; Pedro Mata Journal: Curr Atheroscler Rep Date: 2022-04-07 Impact factor: 5.113
Authors: Anselm K Gitt; Ulrich Laufs; Winfried März; W Dieter Paar; Peter Bramlage; Nikolaus Marx; Klaus G Parhofer Journal: J Clin Med Date: 2022-06-30 Impact factor: 4.964
Authors: Victoria Marco-Benedí; Martin Laclaustra; Juan M Casado-Dominguez; Rosa Villa-Pobo; Rocío Mateo-Gallego; Rosa M Sánchez-Hernández; Marta Blanco Nuez; Emilio Ortega-Martínez de Victoria; Marta Sitges; Juan Pedro-Botet; Jose Puzo; Teresa Villarroel; Fernando Civeira Journal: J Clin Med Date: 2019-12-14 Impact factor: 4.241
Authors: Akl C Fahed; Kamel Shibbani; Rabih R Andary; Mariam T Arabi; Robert H Habib; Denis D Nguyen; Fady F Haddad; Elie Moubarak; Georges Nemer; Sami T Azar; Fadi F Bitar Journal: Cholesterol Date: 2017-07-06
Authors: Sander W van der Laan; Marten A Siemelink; Saskia Haitjema; Hassan Foroughi Asl; Ljubica Perisic; Michal Mokry; Jessica van Setten; Rainer Malik; Martin Dichgans; Bradford B Worrall; Nilesh J Samani; Heribert Schunkert; Jeanette Erdmann; Ulf Hedin; Gabrielle Paulsson-Berne; Johan L M Björkegrenn; Gert J de Borst; Folkert W Asselbergs; Folkert W den Ruijter; Paul I W de Bakker; Gerard Pasterkamp Journal: Circ Genom Precis Med Date: 2018-09